Hormone Health for Women: Perimenopause and What Gets Missed

Perimenopause usually starts years before periods stop, and the symptoms rarely arrive labelled. A great many women are treated for anxiety, insomnia or low mood for a long time before anyone connects the pattern.

Women's hormone health gets a fraction of the attention men's does, despite affecting a transition that every woman who lives long enough goes through. The consequence is a lot of women navigating years of disruptive symptoms without a framework for what is happening.

What perimenopause is

Ovarian function does not switch off. It becomes erratic first. Through perimenopause, follicle numbers decline, ovulation becomes less regular, and oestrogen output swings — sometimes higher than in a normal cycle, sometimes much lower, often within the same month. Progesterone falls as ovulatory cycles become less frequent. FSH rises, but unevenly.

That volatility, rather than a simple decline, explains much of the symptom picture. Women often describe it as feeling unpredictable rather than steadily worse.

The transition commonly begins in the mid-to-late forties, though the range is wide and some women notice changes in their early forties. It typically lasts several years. Menopause is diagnosed retrospectively after twelve consecutive months without menstruation. Symptoms do not necessarily stop there — vasomotor symptoms in particular can continue for years afterwards, and genitourinary symptoms tend to persist and progress rather than resolve.

The symptom picture

Cycle changes

Usually the first sign. Cycles shorten, then lengthen, then become unpredictable. Flow changes. Skipped periods appear and then resume. Because irregularity is the expected pattern, it can be dismissed as unremarkable — but very heavy bleeding, bleeding between periods, bleeding after intercourse or any bleeding after twelve months without a period needs medical assessment rather than attribution to the transition.

Vasomotor symptoms

Hot flushes and night sweats. These are the symptoms most associated with menopause publicly and are experienced by a majority of women, though severity varies enormously. Night sweats in particular do damage indirectly, by fragmenting sleep.

Sleep disruption

Difficulty falling asleep, waking in the early hours, and sleep that does not restore. Some of this is driven by night sweats and some occurs independently. Sustained poor sleep then produces fatigue, irritability, poor concentration and low mood on its own — which is a large part of why the whole picture gets attributed to a primary mood or sleep disorder. Our article on sleep and mental health covers how tightly those threads are wound together.

Mood and cognition

Increased anxiety, irritability, low mood, tearfulness, reduced stress tolerance. Women with a history of premenstrual mood symptoms or postnatal depression appear more vulnerable during this window. Cognitive complaints are common and specific — word-finding difficulty, losing the thread mid-sentence, forgetting why you came into the room. These are distressing partly because women fear they signal something worse. Reassuringly, this pattern is generally described as transitional rather than progressive.

Genitourinary symptoms

Vaginal dryness, discomfort during sex, urinary urgency and recurrent urinary tract infections. These are underreported because women are not asked and often do not raise them. Unlike hot flushes, they typically do not improve with time. They also have some of the most effective and lowest-risk treatments available, which makes the silence around them especially unfortunate.

Everything else

Joint aches, headaches or a change in migraine pattern, palpitations, skin and hair changes, reduced libido, weight redistribution towards the abdomen. Bone loss accelerates around and after menopause, which is silent and is one reason the transition matters medically beyond symptom control.

Why blood tests are usually not the answer here

Women frequently expect a blood test to settle whether they are in perimenopause. In this phase it often cannot.

Hormone levels fluctuate substantially from cycle to cycle and within cycles. An FSH measured in one week can look post-menopausal and, measured a fortnight later, entirely normal. A normal result does not exclude perimenopause and an abnormal one does not confirm it. For women over about forty-five with typical symptoms and changing cycles, guidance generally supports making the diagnosis clinically without hormone testing.

Testing does have a place: younger women, particularly under forty, where premature ovarian insufficiency needs identifying; women who have had a hysterectomy and cannot use cycle changes as a guide; and where the picture is atypical. Thyroid function, full blood count and ferritin are often more useful than sex hormone levels, because they identify the alternatives.

Be sceptical of services selling comprehensive hormone panels as the route to a perimenopause diagnosis. Salivary hormone testing in particular is not supported for this purpose.

Treatment options

What follows describes categories of option. None of it is a recommendation, and what suits an individual depends on her symptoms, medical history, personal risk factors and preferences — which is a conversation with a clinician, not a decision made from an article.

Menopausal hormone therapy

MHT — also called HRT — is the most effective treatment available for vasomotor symptoms and helps several other symptoms including sleep disruption and some mood effects. It typically involves oestrogen, with a progestogen added for women who have a uterus in order to protect the endometrium. Routes include oral tablets and transdermal patches, gels and sprays; transdermal routes are often preferred where clot risk is a consideration, because they avoid first-pass hepatic metabolism.

MHT is not appropriate for everyone. History of breast cancer, certain other hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, and a history of venous thromboembolism or stroke all affect suitability, and some are absolute contraindications. This is precisely why a full history matters.

Vaginal oestrogen

For genitourinary symptoms specifically, low-dose vaginal oestrogen is applied locally with minimal systemic absorption. It is often appropriate for women who are not candidates for or do not want systemic therapy, and it treats a set of symptoms that will not otherwise improve. Non-hormonal vaginal moisturisers and lubricants also have a role.

Non-hormonal prescription options

Certain antidepressants have been shown to reduce hot flushes and are used for that purpose, including in women who cannot take oestrogen. Some other prescription medicines used off-label have evidence for vasomotor symptoms, and newer non-hormonal agents targeting the neural pathway involved in flushing have been developed. Which of these is appropriate is entirely individual.

Approaches without a prescription

Cognitive behavioural therapy has evidence for reducing the distress and impact of hot flushes and for improving sleep. CBT for insomnia is well supported for the sleep component. Regular resistance and weight-bearing exercise supports bone and muscle. Reducing alcohol and managing weight both influence symptom burden. None of these are as effective as MHT for severe vasomotor symptoms, and presenting them as equivalent would be dishonest — but they are genuinely useful, they combine well with medical treatment, and they matter for women who cannot take hormones. Where stress and sleep are dominant, our stress and wellbeing service covers that ground.

The WHI, and what it did and didn't show

This deserves care, because it has been misrepresented in both directions.

In 2002, the Women's Health Initiative — a large randomised trial of hormone therapy in postmenopausal women — halted one of its arms early and reported findings including an increased risk of breast cancer alongside cardiovascular findings that ran contrary to the prevailing expectation that hormone therapy would protect the heart. The reporting was widespread and alarming. Prescribing fell sharply and internationally, and a generation of women either stopped treatment or never started it.

Subsequent analysis complicated that picture. The average participant was substantially older than the women who typically seek treatment for symptoms, and many were years past menopause when they started. Re-analyses stratified by age and time since menopause found the risk-benefit balance differed meaningfully between younger women closer to menopause and older women well beyond it — often described as the timing hypothesis. Different formulations and routes were also shown to carry different risk profiles, and the oestrogen-only arm produced different findings from the combined arm.

What is fair to conclude: the original findings were not fabricated and the risks were not imaginary. The reporting did not convey that the results applied most directly to an older population, and the resulting blanket avoidance left many symptomatic women untreated for years. Current guidance generally supports MHT for symptomatic women without contraindications, with individualised assessment, and is more favourable for women starting nearer the onset of menopause.

What is not fair to conclude: that the WHI was simply wrong, that hormone therapy carries no risk, or that everyone should be on it. Any source telling you either of those things is selling a position.

Getting taken seriously

Go in with specifics. Track cycles, symptoms, timing and impact for a couple of months beforehand — a pattern written down is harder to dismiss than a general sense of feeling off. Say plainly what affects you most, including the genitourinary symptoms most women skip. Ask directly whether perimenopause could explain the picture, and what else is being considered.

If you are offered an antidepressant and it does not fit what you are describing, it is reasonable to ask why that rather than an assessment of the transition — and equally reasonable to accept it if depression is genuinely part of the picture, since it often is. Our article on burnout versus depression covers the difficulty of separating overlapping causes of the same symptoms.

Much of this can be handled remotely, though not all of it — the boundaries are set out in what telehealth is actually good for. You can arrange a consultation to talk through your own situation. That conversation may end in treatment, in further investigation, or in a referral — which is how a clinical assessment is supposed to work.